1. Homozygosity for the F5 c.1296+268A>G splicing mutation causes life-threatening factor V deficiency (Castoldi et al. J Thromb Haemost 2011) 2. Mutation-specific antisense molecules can correct this splicing defect and restore factor V synthesis in the patient's megakaryocytes 
Key points
1
Introduction
Coagulation factor V (FV) is a large glycoprotein produced in the liver and released in the bloodstream as an inactive precursor. Once activated, it acts as a non-enzymatic cofactor of factor Xa (FXa) in the conversion of prothrombin (PT) to thrombin, accelerating this reaction by several orders of magnitude. 1 This essential role in thrombin formation makes FV indispensable to life, as demonstrated by the lethal phenotype of FV knock-out mice. 2 Approximately 80% of FV circulates in plasma, the remaining 20% being stored in platelet α -granules. 3 Although megakaryocytes can synthesise FV, 4 platelet FV originates from secondary endocytosis of plasma FV. [5] [6] [7] FV deficiency [8] [9] [10] is a rare bleeding disorder inherited as an autosomal recessive trait and associated with mutations in the F5 gene. Homozygous and doubly heterozygous individuals present with a strikingly variable bleeding tendency, 11 which is mainly determined by their residual platelet FV. [12] [13] [14] Since no FV concentrate or recombinant FV preparation is available, replacement therapy still relies on the administration of fresh-frozen plasma or platelet concentrates, with all well-known associated risks (volume overload, transmission of infectious agents, immune reactions and transfusion-related acute lung injury).
At least 10% of all F5 mutations are splicing defects, 15 i.e. they disrupt the process by which introns are removed from the primary transcript and exons are joined together to form the mature mRNA. The resulting mature transcript often contains a premature stop codon and is rapidly degraded. Accordingly, F5 splicing mutations are usually associated with severe bleeding symptoms. 14, [16] [17] [18] [19] [20] [21] Several studies on various genetic disorders have shown that splicing defects are amenable to "RNA therapy" with antisense molecules specifically designed to anneal to the mutant pre-mRNA (without triggering its degradation) and to direct its maturation into the correct transcript (reviewed in refs. [22] [23] [24] [25] ). In particular, mutations that disrupt an existing donor splice site can be
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From corrected with U1 small nuclear RNA (snRNA) specifically modified to recognise the mutated splice site, 26 whereas mutations that create a new splice site can be targeted with short antisense oligonucleotides or snRNAs that mask the aberrant splice site and prevent its interaction with the spliceosome. A growing body of in vitro and ex vivo evidence supports the efficacy and safety of antisense-based RNA therapy in several genetic diseases, 23, 24, 27 but only few studies have been conducted in bleeding disorders. [28] [29] [30] The aim of the present study was to design and validate a personalised antisense-based RNA therapy for a previously described patient with severe FV deficiency (undetectable FV in both plasma and platelets), 14 who recently suffered from a second spontaneous intracranial haemorrhage.
The patient is homozygous for a deep-intronic splicing mutation (F5 c.1296+268A>G) activating a cryptic donor splice site in intron 8 and causing the inclusion of a pseudo-exon with an in-frame stop codon in the mature transcript. 14 The efficacy and cytotoxicity of two different antisense molecules targeting this mutation were tested in an in vitro model and ex vivo on patient-derived megakaryocytes.
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Materials and Methods

Antisense molecules
Morpholino oligonucleotide (MO). MOs are uncharged analogues of nucleic acids with a phosphorodiamidate backbone. Two 25-mer MOs were purchased from GeneTools (Philomath, OR, USA), one (rescuer) with a sequence complementary to the mutant F5 pre-mRNA (5'-GGTCACATGGTATCTACTTACCTGT-3', mutation site underlined) and the other (control) with an irrelevant sequence (5'-CCTCTTACCTCAGTTACAATTTATA-3').
Engineered U7snRNA. U7snRNAs are a class of snRNAs involved in the 3'-end processing of histone pre-mRNAs. 31 The U7-SmOPT construct 32 (kindly provided by Dr. D. Schümperli, Bern, Switzerland) consists of a murine U7snRNA gene (including its natural promoter and 3' sequences)
cloned in the pSP64 vector. This construct expresses a 62-nt U7snRNA in which the U7-specific Sm-binding site has been replaced by the Sm-binding site (SmOPT) found in spliceosomal snRNAs.
Using a mutagenic primer, we replaced the anti-histone pre-mRNA sequence with a sequence complementary to the aberrant splice site in the mutant F5 pre-mRNA (5'-TCTACTTACCTGTGGCTTTA-3', mutation site underlined). The ability of this engineered anti-F5 U7snRNA (rescuer) to correct splicing of the mutant F5 pre-mRNA was compared to that of the original anti-histone U7snRNA (control).
In vitro model: COS-1 or HepG2 cells transfected with F5 minigene constructs
Cloning of the F5 minigene. A 2572-bp genomic fragment spanning F5 intron 7 through intron 9 and containing the c.1296+268A>G mutation was amplified from the patient's genomic DNA using the PfuUltra II Fusion HS DNA Polymerase (Agilent Technologies, Amstelveen, The Fluorescence curves were analysed with the LightCycler 480 Software version 1.5 and relative quantification was performed with the 2 -∆∆Ct method. All samples were assayed in duplicate.
Cytotoxicity assays
Potential cytotoxic effects of the antisense molecules and/or delivery agents were evaluated with the xCELLigence System (Roche). Details are reported in the Supplemental Data file. 
Ex vivo model: patient's ex-vivo differentiated megakaryocytes
Results
Splicing correction strategy
The F5 c.1296+268A>G mutation introduces a strong donor splice site deep in intron 8, causing the inclusion of an intronic pseudo-exon with an in-frame stop codon in the mature F5
mRNA. In order to correct this aberrant splicing event, we designed antisense ("rescuer") MO and engineered U7snRNA molecules targeting the mutation site, with the aim to induce pseudo-exon skipping. MO and U7snRNA molecules with irrelevant sequences were used as controls.
In vitro model
To 
Discussion
Antisense-based RNA therapy is rapidly emerging as a promising tool to correct splicing defects. [22] [23] [24] 27 Unlike classical gene therapy, where a functional copy of the defective gene (cDNA)
under control of a strong promoter is introduced in the patient's cells, RNA therapy relies on short mutation-specific antisense oligonucleotides or engineered snRNAs that anneal to the mutant primary transcript and re-direct its maturation into the correct mRNA. By acting at the RNA rather than DNA level, this form of molecular therapy does not affect the transcriptional regulation of the targeted gene (or any other gene).
Despite the encouraging results obtained in several genetic diseases, the potential utility of RNA therapy in coagulation disorders is only just beginning to be explored. 25 Among all coagulation factor deficiencies, FV deficiency represents a particularly suitable target for RNA therapy, because: a) no FV concentrate or recombinant FV preparation is available for substitutive therapy; b) the FV requirement for adequate haemostasis is extremely low, making a few % FV sufficient to prevent life-threatening bleeding; 19, [35] [36] [37] and c) the large size of the F5 cDNA makes conventional gene therapy particularly challenging. Here we present the first application of RNA therapy to severe FV deficiency and we provide in vitro and ex vivo evidence that mutation-specific antisense molecules can effectively rescue a F5 splicing mutation.
The mutation that we have targeted (F5 c.1296+268A>G) activates a cryptic donor splice site deep in intron 8, causing the retention of an intronic pseudo-exon in the mature mRNA.
14 Although this is presently the only known F5 splicing defect that can be corrected through MO-or U7snRNA-mediated pseudo-exon skipping, deep-intronic splicing mutations may be more prevalent than previously suspected. 38 In fact, deep-intronic splicing mutations potentially amenable to this corrective approach have been identified in the F8, [39] [40] [41] [42] The F5 c.1296+268A>G mutation was originally identified in the homozygous state in a patient with undetectable FV and a life-threatening bleeding diathesis. 14 To prove that our antisense MO and U7snRNA could rescue the patient's FV deficiency, we showed that they could effectively correct the F5 mRNA splicing pattern and restore FV expression in the patient's ex vivo differentiated megakaryocytes. Although megakaryocytes are not the physiological site of FV production in vivo, [5] [6] [7] they have been shown to synthesise FV in culture, 4 offering us the opportunity to test the antisense molecules on the patient's own cells without a liver biopsy. Unfortunately, the antisense molecules could not be tested directly on the patient's hepatocytes, but their efficacy in correcting the splicing defect in HepG2 cells transfected with the mutant F5 minigene construct suggests that they would be able to restore FV expression in the patient's hepatocytes as well,
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From especially considering the fact that the liver is a preferential site of accumulation of systemically injected MOs. 44, 45 Treatment with rescuer (and control) MO and U7snRNA molecules adversely affected the viability and/or proliferation of COS-1 and (to a much lesser extent) HepG2 cells in in vitro cytotoxicity assays. However, toxic effects were largely attributable to the transfection reagents used to deliver the antisense molecules rather than to the antisense molecules themselves. Since the delivery of antisense molecules to target cells in vivo does not rely on transfection reagents, but rather on free uptake by body cells (MOs) 46 or on targeted delivery using engineered viral vectors (U7snRNAs), 47 major adverse effects in treated patients appear unlikely. In fact, antisense molecules have shown excellent safety profiles in several in vivo studies of other genetic diseases, both in animal models and in human volunteers, being well tolerated even after systemic administration. 44, 47 Nevertheless, since each antisense molecule has a unique sequence, off-target effects can never be excluded.
In summary, our data show that specific antisense molecules targeting the c.1296+268A>G 
